Form 8-K - Current report:
SEC Accession No. 0001628280-21-023902
Filing Date
2021-11-19
Accepted
2021-11-19 17:17:05
Documents
16
Period of Report
2021-11-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20211119.htm   iXBRL 8-K 39219
2 EX-99.1 a11-19x21ex991.htm EX-99.1 19345
7 GRAPHIC image_0.jpg GRAPHIC 21572
8 GRAPHIC image_1.jpg GRAPHIC 23268
  Complete submission text file 0001628280-21-023902.txt   284945

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20211119.xsd EX-101.SCH 2265
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cpix-20211119_def.xml EX-101.DEF 13058
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20211119_lab.xml EX-101.LAB 26049
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20211119_pre.xml EX-101.PRE 13936
9 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20211119_htm.xml XML 11025
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 211429336
SIC: 2834 Pharmaceutical Preparations